EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

What exactly drives a company's stock price higher? Intuitively, it's investor demand, but dig deeper — why are investors flocking to buy certain stocks beyond just fear of missing out?

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

Longer Term Trading Plans for CRSP. Buy CRSP near 40.82 target 52.08 stop loss @ 40.7 Details; The technical summary data ...

What small-capitalization stocks can add to your portfolio and how much you should allocate to them. Plus, we identify some ...

On Tuesday, TD (TSX:TD) Cowen maintained a Sell rating on CRISPR Therapeutics (NASDAQ:CRSP) shares with a steady price target of $30.00. The firm's analysis adjusted the Q2 ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $45.71, demonstrating a +0.29% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain ...